Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents

Annals of Oncology

Volumn 25, Issue 1, 2014, Pages 195-200

  Dimopoulos, M A ^a   Delimpasi, S ^a   Katodritou, E ^a   Vassou, A ^a   Kyrtsonis, M C ^a   Repousis, P ^a   Kartasis, Z ^a   Parcharidou, A ^a   Michael, M ^a   Michalis, E ^a   Gika, D ^a   Symeonidis, A ^a   Pouli, A ^a   Konstantopoulos, K ^a   Terpos, E ^a   Kastritis, E ^a  

^a Greek Myeloma Study Group   (Greece)

Author keywords

Bortezomib; Elderly; Lenalidomide; Renal impairment; Thalidomide

Indexed keywords

ANTHRACYCLINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK FACTOR; RISK REDUCTION; SEVERE RENAL IMPAIRMENT; TREATMENT OUTCOME;

BORTEZOMIB; ELDERLY; LENALIDOMIDE; RENAL IMPAIRMENT; THALIDOMIDE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PYRAZINES; RENAL INSUFFICIENCY; RISK; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84903904015     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt483     Document Type: Article

References (13)

1. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathog prognostic implications. Arch Intern Med 1990; 150(8): 1693-1695.
2. Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78(1): 21-33.
3. Augustson BM, Begum G, Dunn JA et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005; 23(36): 9219-9226.
4. Kastritis E, Terpos E, Dimopoulos MA. Current treatments for renal failure due to multiple myeloma. Expert Opin Pharmacother 2013; 14(11): 1477-1495.
5. Dimopoulos MA, Terpos E, Chanan-Khan A et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28(33): 4976-4984.
6. Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111(5): 2516-2520. 10.1182/blood-2007-10-116129.
7. Kastritis E, Zervas K, Symeonidis A et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009; 23(6): 1152-1157.
8. Dimopoulos MA, Roussou M, Gkotzamanidou M et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia 2013; 27(2): 423-429.
9. Kastritis E, Anagnostopoulos A, Roussou M et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 2007; 92(4): 546-549.
10. Roussou M, Kastritis E, Christoulas D et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 2010; 34(10): 1395-1397.
11. Turesson I, Velez R, Kristinsson SY et al. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc 2010; 85(3): 225-230.
12. Dimopoulos MA, Kastritis E, Delimpasi S et al. Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era. Eur J Haematol 2012; 89(1): 10-15.
13. Ludwig H, Adam Z, Hajek R et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 2010; 28(30): 4635-4641.